NEW YORK, July 20, 2026, 1:57 p.m. EDT
Shares of Personalis NASDAQ:PSNL dropped 11.6% on Monday, even after receiving a $16.25 acquisition bid. Tempus AI NASDAQ:TEM, which is seeking to buy Personalis, declined 6.2%. The Nasdaq Composite rose 0.35% as U.S. markets remained open.
At 1:41 p.m. EDT, Personalis shares changed hands at $13.61, representing a 16.2% discount to the headline offer.
The deal reflects an enterprise value of $1.5 billion, adjusted for Tempus’s shareholding. Tempus can choose to take up to half the consideration in cash; the remainder will be settled with a variable stock ratio if not.
The headline premium was modest, with the offer only 5.6% higher than Friday’s closing price of $15.39. The stated 28% premium indicates an unaffected VWAP of around $12.70. Approximately 76% of the overall increase was already reflected in Friday’s closing price.
The cap on the exchange ratio narrows the calculations. The highest possible is 0.3356 Tempus shares for each Personalis share, equating to $16.25 if Tempus stock is at $48.42. At that time, Tempus shares were trading just 1.6% higher than this threshold.
| Comparison | Market or deal level | Investor implication |
|---|---|---|
| Personalis at 1:41 p.m. | $13.61, off 11.6% | Trading 16.2% below offer price |
| Tempus at 1:41 p.m. | $49.20, off 6.2% | Standing 1.6% above cap line |
| Nasdaq Composite | 25,608.79, higher by 0.35% | Index trades higher overall |
| Friday close | $15.39 | Offer marked a 5.6% premium |
| Implied unaffected VWAP | About $12.70 | Offer reflected a 28% premium |
Figures for the market are as of 1:41 p.m. EDT. The calculations are based on the published details of the transaction.
If the price drops below $48.42, the stock payment with the cap is less than the headline figure. When the price is $46, the capped all-stock payment amounts to roughly $15.44. Should the price fall under $46, Personalis can exercise a termination right.
Guggenheim analyst Subbu Nambi connected the drop in shares to the stock-based deal structure. Nambi noted that Personalis shareholders were doubtful about Tempus’s potential benefits.
Tempus has announced the acquisition of NeXT Personal, a blood-based test designed to detect minimal residual disease. The two firms have collaborated since November 2023. Tempus puts the value of the MRD market at $20 billion.
Roughly 10% of Tempus’s sales team currently markets NeXT Personal. The buyer described expanding distribution as a chance for growth.
Personalis announced estimated second-quarter revenue of $22.4 million. The company’s clinical volume totaled 10,384 tests, representing a 33% increase from the previous quarter.
Tempus held off, Chief Executive Eric Lefkofsky said. He aimed for the company to “quickly turn into a really healthy business” in terms of gross profit and margins. Reuters
The transaction received approval from both boards. The deal is anticipated to close in late 2026 or early 2027, pending shareholder and regulatory clearance.
Potential risks are added weakness in Tempus, an unsuccessful vote, or regulatory holdups. Delays in reimbursement or challenges with integration might also undermine the financial aspects of the deal.
The spread is now following Tempus rather than the $16.25 figure. Important thresholds are set at $48.42 for the cap and $46 as the point for termination risk.
